LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

Home・Aandelen Lijst・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorGezondheidszorg

1.91 10.4

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.67

Max

1.9100000000000001

Belangrijke statistieken
By Trading Economics
Inkomsten	1.2M -31M
Verkoop	-70K 1.3M
EPS	-0.26
Winstmarge	-2,402.848
Werknemers	161
EBITDA	12M -30M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+153.76% upside

Dividenden
By Dow Jones
Volgende Winsten	10 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-52M 202M
Vorige openingsprijs	-8.49
Vorige sluitingsprijs	1.91

Nieuwssentiment

By Acuity

46%

54%

157 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

0.9101 / 1.14 Steun & Weerstand

Fate Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 mei 2026, 20:36 UTC

Acquisities, Fusies, Overnames

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 mei 2026, 23:34 UTC

Marktinformatie

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 mei 2026, 23:28 UTC

Marktinformatie

Winsten

Global Forex and Fixed Income Roundup: Market Talk

19 mei 2026, 23:28 UTC

Marktinformatie

Winsten

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 mei 2026, 23:10 UTC

Marktinformatie

Global Equities Roundup: Market Talk

19 mei 2026, 23:10 UTC

Marktinformatie

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 mei 2026, 22:02 UTC

Winsten

ZTO Express (Cayman): Di Xu to Resign From Board

19 mei 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 mei 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 mei 2026, 22:00 UTC

Winsten

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 mei 2026, 21:37 UTC

Winsten

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 mei 2026, 21:31 UTC

Acquisities, Fusies, Overnames

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 mei 2026, 21:01 UTC

Winsten

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 mei 2026, 20:58 UTC

Winsten

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 mei 2026, 20:46 UTC

Populaire aandelen

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 mei 2026, 20:43 UTC

Marktinformatie

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 mei 2026, 20:34 UTC

Winsten

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 mei 2026, 20:32 UTC

Winsten

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 mei 2026, 20:32 UTC

Winsten

James Hardie Industries 4Q EPS 5c >JHX

19 mei 2026, 20:32 UTC

Winsten

James Hardie Industries 4Q Sales $1.4B >JHX

19 mei 2026, 20:21 UTC

Acquisities, Fusies, Overnames

Analog Devices to Buy Empower Semiconductor for $1.5B

19 mei 2026, 20:18 UTC

Marktinformatie

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 mei 2026, 20:13 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

19 mei 2026, 20:13 UTC

Marktinformatie

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 mei 2026, 20:03 UTC

Acquisities, Fusies, Overnames

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 mei 2026, 20:03 UTC

Acquisities, Fusies, Overnames

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 mei 2026, 20:02 UTC

Acquisities, Fusies, Overnames

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 mei 2026, 20:02 UTC

Acquisities, Fusies, Overnames

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 mei 2026, 19:23 UTC

Marktinformatie

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Peer Vergelijking

Prijswijziging

Fate Therapeutics Inc Prognose

Koersdoel

By TipRanks

153.76% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.39 USD 153.76%

Hoogste 7 USD

Laagste 2 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fate Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Fate Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.9101 / 1.14Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

157 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.